Latest Posts
About This Stock
More About This Stock
Read
Read
GenSight Biologics IPO
Article By:
IPO Candy
Thursday, November 5, 2015 10:30 AM EDT
GenSight is a smaller size biotech deal with Leerick, Evercore and Canaccord on the cover. The 4.6M shares are all primary with a $14 mid-point. Post-IPO there will be close to 19M shares with a market cap of $270m.
Harness Biotech Volatility With An Options Strategy: Theta Strategy Capital's Eden Rahim
Article By:
The Life Sciences Report
Friday, August 14, 2015 4:13 AM EDT
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital.
In this article: ABT, AGN, SGYP, RPTP, MBXBF, PWCDF, RHHBY, SSDOY, ACAD, DNDN, FOLD, HALO, ILMN, MDVN, AMGN, BIIB, SHPG, REPCF, SUPN, BCLI, ITEK, RARE, PTLA, CPHR, PTGEF, BLUSF